Two-in-One Type 2 Diabetes Drug Gets Approval

Merck's Janumet gives physicians another treatment option

TUESDAY, April 3 (HealthDay News) -- The U.S. Food and Drug Administration has approved a diabetes drug called Janumet that combines metformin and the dipeptidyl peptidase-4 inhibitor, sitagliptin. Janumet has been approved for patients with type 2 diabetes who already take both components separately or who take only one of the components and have not achieved adequate blood sugar control.

The drug's efficacy was illustrated in a clinical trial involving 701 type 2 diabetics whose blood sugar was not adequately controlled on metformin. Of the 453 given Janumet, 213 (47 percent) attained the American Diabetes Association's average blood glucose goal of less than 7 percent, compared with only 41 of the 224 patients (18 percent) given placebo.

In another trial comparing Janumet with metformin, patients lost a similar amount of weight on both drugs, but those taking Janumet had slightly lower risk of hypoglycemia, edema and gastrointestinal adverse reactions.

"Janumet is an important new treatment option for many patients who need more than one therapy to control their type 2 diabetes because it addresses all three key defects of type 2 diabetes for improved glycemic control," said Nir Barzilai, M.D., of the Albert Einstein College of Medicine, Bronx, N.Y., in a statement released by the manufacturer, Merck & Co. of Whitehouse Station, N.J.

More Information - Merck

Physician's Briefing